Clinical effects of antiplatelet drugs and statins on D-dimer levels
- PMID: 29682728
- PMCID: PMC6055760
- DOI: 10.1111/eci.12944
Clinical effects of antiplatelet drugs and statins on D-dimer levels
Abstract
Background: Acute pulmonary embolism may be ruled out by combining nonhigh clinical probability and a normal D-dimer level. Both antiplatelet drugs and HMG-CoA reductase inhibitors (statins) have been associated with effects on thrombus formation, potentially influencing D-dimer levels in this setting, leading to a higher rate of false-negative tests. Therefore, we determined whether D-dimer levels in patients with suspected pulmonary embolism are affected by concomitant use of antiplatelet drugs and/or statins and evaluated whether the effect of antiplatelet drugs or statins might affect diagnostic accuracy.
Materials and methods: We performed a posthoc analysis in the YEARS diagnostic study, comparing age- and sex-adjusted D-dimer levels among users of antiplatelet drugs, statins and nonusers. We then reclassified patients within the YEARS algorithm by developing a model in which we adjusted D-dimer cut-offs for statin use and evaluated diagnostic accuracy.
Results: We included 156 statins users, 147 antiplatelet drugs users and 726 nonusers of either drugs, all with suspected pulmonary embolism. Use of antiplatelet drugs did not have a significant effect, whereas statin use was associated with 15% decrease in D-dimer levels (95% CI, -28% to -0.6%). An algorithm with lower D-dimer thresholds in statin users yielded lower specificity (0.42 compared to 0.33) with no difference in false-negative tests.
Conclusions: We conclude that use of statins but not of antiplatelet agents is associated with a modest decrease in D-dimer levels. Adjusting D-dimer cut-offs for statin use did, however, not result in a safer diagnostic strategy in our cohort.
Keywords: fibrin fragment D; hydroxymethylglutaryl-CoA reductase inhibitors; platelet aggregation inhibitors; pulmonary embolism; venous thromboembolism.
© 2018 The Authors European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Figures

Similar articles
-
A revised systematic review and meta-analysis on the effect of statins on D-dimer levels.Eur J Clin Invest. 2019 Aug;49(8):e13130. doi: 10.1111/eci.13130. Epub 2019 Jun 3. Eur J Clin Invest. 2019. PMID: 31112290
-
Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.JAMA. 2014 Mar 19;311(11):1117-24. doi: 10.1001/jama.2014.2135. JAMA. 2014. PMID: 24643601
-
Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.J Thromb Haemost. 2013 Jun;11(6):1078-84. doi: 10.1111/jth.12223. J Thromb Haemost. 2013. PMID: 23565981 Free PMC article.
-
Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study.Lancet. 2017 Jul 15;390(10091):289-297. doi: 10.1016/S0140-6736(17)30885-1. Epub 2017 May 23. Lancet. 2017. PMID: 28549662 Clinical Trial.
-
Effect of Antiplatelet Drugs on D-Dimer Levels: A Systematic Review and Meta-analysis.J Cardiovasc Pharmacol. 2019 Jun;73(6):343-351. doi: 10.1097/FJC.0000000000000670. J Cardiovasc Pharmacol. 2019. PMID: 31162242
Cited by
-
Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation.Front Cardiovasc Med. 2021 Apr 20;8:657719. doi: 10.3389/fcvm.2021.657719. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33959645 Free PMC article. No abstract available.
-
Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond.Front Pharmacol. 2021 Jan 19;11:579548. doi: 10.3389/fphar.2020.579548. eCollection 2020. Front Pharmacol. 2021. PMID: 33542685 Free PMC article. No abstract available.
-
Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence.Adv Exp Med Biol. 2023;1408:25-47. doi: 10.1007/978-3-031-26163-3_2. Adv Exp Med Biol. 2023. PMID: 37093420 Review.
-
Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism.Front Cardiovasc Med. 2021 Oct 13;8:711923. doi: 10.3389/fcvm.2021.711923. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34722654 Free PMC article. No abstract available.
-
Screening for Deep Vein Thrombosis Using D-dimer Levels Based on Surgical Patients' Characteristics.Cureus. 2024 Dec 11;16(12):e75565. doi: 10.7759/cureus.75565. eCollection 2024 Dec. Cureus. 2024. PMID: 39803096 Free PMC article.
References
-
- Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2015;36:2642. - PubMed
-
- Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the clinical guidelines committee of the american college of physicians. Ann Intern Med. 2015;163:701‐711. - PubMed
-
- van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017;390:289‐297. - PubMed
-
- Adam SS, Key NS, Greenberg CS. D‐dimer antigen: current concepts and future prospects. Blood. 2009;113:2878‐2887. - PubMed
-
- Douma RA, van Sluis GL, Kamphuisen PW, et al. Clinical decision rule and D‐dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost. 2010;104:831‐836. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical